Patients with head and neck cancer who consumed a diet high in nutrients found to deter chronic disease had a 93% lower likelihood of death due to any cause during the first 3 years after diagnosis, according to study results.The findings, published in Frontiers in Nutrition, could be instrumental in the creation of future studies of dietary interventions and medical nutrition therapy guidelines

Stereotactic body radiation therapy combined with single-dose durvalumab before surgery appeared safe and induced durable responses among patients with HPV-unrelated locally advanced head and neck cancer, according to study results.The findings of the phase 1/1b study, published in Nature Cancer, laid the groundwork for a larger, ongoing phase 2 trial.

CHICAGO — Docetaxel prolonged DFS and OS when added to radiation for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, according to study results presented at ASCO Annual Meeting.The addition of docetaxel also did not appear to worsen quality of life at 6 months, researchers concluded.

Circulating tumor tissue-modified viral HPV DNA detected through a new assay appeared associated with nodal disease burden among patients with HPV-positive oropharyngeal squamous cell carcinoma, according to study results.The findings, published in JAMA Otolaryngology Head and Neck Surgery, showed the assay did not detect clinical stage N0 disease; thus, sensitivity of the assay may be lower

Black patients in head and neck cancer clinical trials consistently achieved poorer survival than white patients who received the same treatments, according to study results.The finding — based on an analysis of seven Radiation Therapy Oncology Group trials — suggests potential biologic variables may contribute to worse outcomes in head and neck cancer, in addition to previously

Patients with nasopharyngeal cancer who underwent COVID-19 vaccination had a better response to a combination of anti-PD-1 therapy and chemotherapy than their unvaccinated counterparts, according to a letter published in Annals of Oncology.In addition, patients who received the CoronaVac COVID-19 vaccine (Sinovac Biotech) did not have a higher rate of adverse events from the cancer treatment than